_:ne6f63ce7da374884a99e9adfe5e51f5fxb4
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>
<http://schema.org/ListItem>
<https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering>